Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of COV795 in Osteoarthritis or Chronic Low Back Pain
NCT01451385Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Sep 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxycodone + acetaminophen in osteoarthritis (OA) and chronic low back pain (CLBP), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Summary of Adverse Events at 5 weeks. Started Sep 2011; status: completed.
02
Drugs
oxycodone + acetaminophen
03
Conditions
osteoarthritis (OA)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT01451385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01451385.